Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Viking Therapeutics, Inc. VKTX

Healthcare  —  Biotechnology
35.56 (1.19) (3.24%) as of 25 Sep
Market cap
$4.3B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viking Therapeutics, Inc. (VKTX) Business Profile

Updated before January 2025

Company Overview

Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics has established itself as a key player in the biotechnology sector. The company was founded with the mission of addressing unmet medical needs through the development of novel therapeutics.

The leadership team at Viking Therapeutics is composed of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and clinical research. The company is led by Brian Lian, Ph.D., who serves as the President and Chief Executive Officer. Dr. Lian has been instrumental in driving the company’s strategic direction and advancing its clinical pipeline. Other key members of the leadership team include Gregory Zante, Chief Financial Officer, and Charles Rowland, Chairman of the Board of Directors. Together, the leadership team has positioned Viking Therapeutics as a forward-thinking and innovative organization in the biopharmaceutical industry.

Core Business Segments

Viking Therapeutics focuses on the development of therapies targeting metabolic and endocrine disorders. The company’s core business segments include:

1. Metabolic Disorders

Viking Therapeutics is actively developing therapies for metabolic disorders, with a particular focus on non-alcoholic steatohepatitis (NASH) and lipid metabolism. The company’s lead product candidate in this segment is VK2809, a novel liver-selective thyroid hormone receptor beta (TRβ) agonist. VK2809 is being developed for the treatment of NASH and hypercholesterolemia. The drug has shown promising results in clinical trials, demonstrating significant reductions in liver fat content and improvements in lipid profiles.

2. Muscle and Bone Disorders

Another key area of focus for Viking Therapeutics is the development of therapies for muscle and bone disorders. VK5211, a selective androgen receptor modulator (SARM), is the company’s lead candidate in this segment. VK5211 is being developed for the treatment of muscle wasting and bone-related conditions, such as hip fracture recovery. The drug has demonstrated potential in increasing lean body mass and improving physical function in clinical studies.

3. Endocrine Disorders

Viking Therapeutics is also exploring therapies for endocrine disorders. The company’s pipeline includes early-stage programs targeting conditions such as diabetes and obesity. These programs aim to address the growing global burden of endocrine-related diseases by developing innovative and effective treatments.

Business Model

Viking Therapeutics operates as a clinical-stage biopharmaceutical company, which means its primary focus is on research and development (R&D) rather than commercial product sales. The company’s business model revolves around the following key components:

  • Research and Development: Viking Therapeutics invests heavily in R&D to advance its pipeline of product candidates. The company collaborates with leading academic institutions and research organizations to leverage cutting-edge science and technology.
  • Clinical Trials: The company conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. These trials are essential for obtaining regulatory approval and bringing new therapies to market.
  • Partnerships and Licensing: Viking Therapeutics seeks strategic partnerships and licensing agreements to support the development and commercialization of its therapies. These collaborations provide access to additional resources and expertise.
  • Revenue Generation: As a clinical-stage company, Viking Therapeutics does not yet generate revenue from product sales. Instead, the company relies on funding from investors, partnerships, and grants to support its operations.

Strategic Direction

Viking Therapeutics is committed to advancing its clinical pipeline and expanding its therapeutic portfolio. The company’s strategic priorities include:

  • Advancing VK2809: Viking Therapeutics is focused on completing clinical trials for VK2809 and obtaining regulatory approval for its use in treating NASH and hypercholesterolemia. The company aims to position VK2809 as a best-in-class therapy for these conditions.
  • Expanding the Pipeline: Viking Therapeutics is actively exploring new therapeutic areas and expanding its pipeline of product candidates. The company is particularly interested in addressing unmet medical needs in metabolic, muscle, and endocrine disorders.
  • Sustainability Goals: While not explicitly stated, Viking Therapeutics recognizes the importance of sustainability in the biopharmaceutical industry. The company is committed to ethical research practices and minimizing its environmental impact.
  • Global Reach: Viking Therapeutics aims to expand its presence in international markets and make its therapies accessible to patients worldwide.

Competitive Landscape

Viking Therapeutics operates in a highly competitive biopharmaceutical industry. The company faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Madrigal Pharmaceuticals: Madrigal is a leading competitor in the NASH space, with its own TRβ agonist in development.
  • Intercept Pharmaceuticals: Intercept is another major player in the NASH market, with its drug Ocaliva already approved for primary biliary cholangitis (PBC) and under investigation for NASH.
  • Amgen and Regeneron: These large pharmaceutical companies have a strong presence in the metabolic and endocrine disorder markets, with extensive R&D capabilities and resources.
  • Emerging Biotech Firms: Smaller biotech companies focused on metabolic and endocrine disorders also pose competition to Viking Therapeutics.

Risk Factors

Like any biopharmaceutical company, Viking Therapeutics faces several risks, including:

  • Regulatory Risks: The company’s product candidates must undergo rigorous clinical trials and obtain regulatory approval before they can be marketed. Delays or failures in the approval process could impact the company’s growth.
  • Market Dependence: Viking Therapeutics is heavily reliant on the success of its lead product candidates, VK2809 and VK5211. Any setbacks in their development could significantly affect the company’s prospects.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its product candidates. Disruptions in the supply chain could delay clinical trials and commercialization efforts.
  • Financial Risks: As a clinical-stage company, Viking Therapeutics does not generate revenue from product sales and relies on external funding. Limited financial resources could constrain the company’s ability to advance its pipeline.

Recent Developments

Viking Therapeutics has made significant progress in advancing its clinical pipeline. Recent developments include:

  • VK2809 Clinical Trials: The company announced positive results from Phase 2b clinical trials of VK2809, demonstrating its potential as a treatment for NASH and hypercholesterolemia. Viking Therapeutics is now preparing for Phase 3 trials.
  • Pipeline Expansion: Viking Therapeutics has initiated early-stage programs targeting new therapeutic areas, including diabetes and obesity.
  • Corporate Strategies: The company has strengthened its leadership team and secured additional funding to support its R&D efforts.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of innovative therapies, and Viking Therapeutics remains committed to addressing unmet medical needs despite global challenges.

Investment Considerations

Investors considering Viking Therapeutics should weigh the following strengths and risks:

Strengths

  • Promising clinical pipeline with lead candidates VK2809 and VK5211.
  • Experienced leadership team with a strong track record in biotechnology.
  • Focus on addressing unmet medical needs in high-growth therapeutic areas.
  • Strategic partnerships and collaborations to support R&D efforts.

Risks

  • Dependence on the success of lead product candidates.
  • Regulatory and clinical trial risks.
  • Financial constraints as a clinical-stage company.
  • Competition from established pharmaceutical companies and emerging biotech firms.

Conclusion

Viking Therapeutics, Inc. is a dynamic and innovative biopharmaceutical company with a strong focus on metabolic and endocrine disorders. The company’s promising clinical pipeline, experienced leadership team, and commitment to addressing unmet medical needs position it as a key player in the biotechnology sector. While the company faces risks associated with its clinical-stage status and competitive landscape, its strategic direction and recent developments suggest a bright future. Investors and stakeholders should closely monitor Viking Therapeutics as it continues to advance its pipeline and pursue regulatory approvals for its lead product candidates.